While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...

Merck & Co posted higher-than-expected third-quarter earnings on Thursday on strong sales of its blockbuster cancer treatment ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Merck (MRK) to $123 from $130 and keeps an Equal Weight rating on the shares. The Q3 reported highlighted ongoing uncertainty ...

MERCK lowered the top end of its full-year sales guidance after demand for its HPV vaccine fell for a second straight quarter in China. Sales of the Gardasil shot, which is given to teenagers and ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), reducing the price ...

Oct 31 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's distributor there reduces inventories ...

(Reuters) -Merck & Co said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's distributor there reduces inventories amid low demand, and the U.S.